• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受手术及术后调强放疗的涎腺癌患者的肿瘤学结局:一项回顾性队列研究

Oncological outcomes of patients with salivary gland cancer treated with surgery and postoperative intensity-modulated radiotherapy: a retrospective cohort study.

作者信息

Zang Shoumei, Chen Meiqin, Huang Huijie, Zhu Xinli, Li Xinke, Yan Danfang, Yan Senxiang

机构信息

Department of Radiation Oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Department of Radiation Oncology, Affiliated Jinhua Hospital, College of Medicine, Zhejiang University, Jinhua, China.

出版信息

Quant Imaging Med Surg. 2022 May;12(5):2841-2854. doi: 10.21037/qims-21-836.

DOI:10.21037/qims-21-836
PMID:35502385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9014160/
Abstract

BACKGROUND

Salivary gland cancer (SGC) is relatively rare and constitutes a variety of histological subtypes. Previously published studies of SGC patients suggest that postoperative radiation using conventional radiotherapy (RT) or 3-dimensional (3D) conformal radiotherapy may have led to suboptimal oncological outcomes.

METHODS

We identified 60 patients with major SGC treated with surgery followed by postoperative intensity-modulated radiotherapy (IMRT). Data for overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), prognostic factors, and treatment-related toxicities were analyzed. Survival was analyzed using the Kaplan-Meier method and compared using the log-rank test.

RESULTS

With a median follow-up of 55.5 months, based on Kaplan-Meier analyses, the OS and PFS rates for SGC patients at 3, 5, and 10 years were 90.7%, 85.1%, and 85.1% and 80.1%, 72.7%, and 63.1%, respectively. The LRRFS and DMFS rates at 3, 5, and 10 years were 87.4%, 82.1%, and 82.1% and 85.3%, 78.4%, and 66.1%, respectively. In multivariable analysis (MVA), the node stage (N stage) was an independent predictor of PFS [P=0.047; hazard ratio (HR) =0.089]. A positive margin was a significant prognostic factor for PFS (P=0.036; HR =4.086), LRRFS (P=0.026; HR =5.064), and DMFS (P=0.011; HR =6.367). Major nerve involvement was significantly correlated with PFS (P=0.034; HR =2.394) and DMFS (P=0.008; HR =2.115). The interval from surgery to radiotherapy predicted PFS (P=0.036; HR =3.934) and DMFS (P=0.012; HR =6.231). Adenoid cystic carcinoma (ACC) was the most common histology (n=21; 35%). For ACC, the 5-year OS, PFS, LRRFS, and DMFS were 100%, 67.7%, 76.2%, and 90.2%, respectively. The most common acute toxicities were mucositis and dermatitis, and xerostomia was the most common late adverse event. Lung metastasis was the most common pattern of distant failure.

CONCLUSIONS

N stage, positive margin, major nerve involvement, and interval from surgery to radiotherapy were important factors associated with PFS, LRRFS, and DMFS. Postoperative IMRT leads to improved survival for SGC patients, with acceptable toxicities.

摘要

背景

涎腺癌(SGC)相对罕见,包含多种组织学亚型。先前发表的关于涎腺癌患者的研究表明,使用传统放疗(RT)或三维(3D)适形放疗进行术后放疗可能导致肿瘤学结局欠佳。

方法

我们纳入了60例接受手术治疗并随后接受术后调强放疗(IMRT)的主要涎腺癌患者。分析了总生存期(OS)、无进展生存期(PFS)、局部区域无复发生存期(LRRFS)、远处无转移生存期(DMFS)、预后因素及治疗相关毒性的数据。采用Kaplan-Meier法分析生存期,并使用对数秩检验进行比较。

结果

中位随访时间为55.5个月,基于Kaplan-Meier分析,涎腺癌患者3年、5年和10年的OS率分别为90.7%、85.1%和85.1%,PFS率分别为80.1%、72.7%和63.1%。3年、5年和10年的LRRFS率分别为87.4%、82.1%和82.1%,DMFS率分别为85.3%、78.4%和66.1%。在多变量分析(MVA)中,淋巴结分期(N分期)是PFS的独立预测因素[P = 0.047;风险比(HR)= 0.089]。切缘阳性是PFS(P = 0.036;HR = 4.086)、LRRFS(P = 0.026;HR = 5.064)和DMFS(P = 0.011;HR = 6.367)的显著预后因素。主要神经受累与PFS(P = 0.034;HR = 2.394)和DMFS(P = 0.008;HR = 2.115)显著相关。从手术到放疗的间隔时间可预测PFS(P = 0.036;HR = 3.934)和DMFS(P = 0.012;HR = 6.231)。腺样囊性癌(ACC)是最常见的组织学类型(n = 21;35%)。对于ACC,5年OS、PFS、LRRFS和DMFS分别为100%、67.7%、76.2%和90.2%。最常见的急性毒性反应是黏膜炎和皮炎,口干是最常见的晚期不良事件。肺转移是最常见的远处失败模式。

结论

N分期、切缘阳性、主要神经受累以及从手术到放疗的间隔时间是与PFS、LRRFS和DMFS相关的重要因素。术后IMRT可提高涎腺癌患者的生存率,且毒性可接受。

相似文献

1
Oncological outcomes of patients with salivary gland cancer treated with surgery and postoperative intensity-modulated radiotherapy: a retrospective cohort study.接受手术及术后调强放疗的涎腺癌患者的肿瘤学结局:一项回顾性队列研究
Quant Imaging Med Surg. 2022 May;12(5):2841-2854. doi: 10.21037/qims-21-836.
2
[Technical advancement improves survival in patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving definitive radiotherapy].[技术进步改善了接受根治性放疗的局部晚期非小细胞肺癌(LA-NSCLC)患者的生存率]
Zhonghua Zhong Liu Za Zhi. 2016 Aug;38(8):607-14. doi: 10.3760/cma.j.issn.0253-3766.2016.08.008.
3
Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.调强放疗与二维常规放疗相比可延长鼻咽癌患者的生存时间:一项 10 年大样本队列和长期随访研究。
Eur J Cancer. 2015 Nov;51(17):2587-95. doi: 10.1016/j.ejca.2015.08.006. Epub 2015 Aug 26.
4
Long-term treatment outcomes/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage "bulky" cervical cancer and survival impact of histological subtype.早期“体积较大”宫颈癌的确定性放化疗(调强放射治疗)的长期治疗结果/毒性以及组织学亚型对生存的影响
J Formos Med Assoc. 2023 Mar;122(3):221-229. doi: 10.1016/j.jfma.2022.10.012. Epub 2022 Nov 12.
5
The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric modulated arc therapy.同步放化疗治疗宫颈癌患者的预处理鳞状细胞癌抗原水平的预后意义,以及调强放疗和容积旋转调强放疗的剂量学结果和临床毒性比较。
Radiat Oncol. 2022 May 12;17(1):91. doi: 10.1186/s13014-022-02063-w.
6
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.度伐利尤单抗用于局部晚期非小细胞肺癌放化疗后的临床实践结果显示,其显著延长了无远处转移生存期、无进展生存期和总生存期。
BMC Cancer. 2022 Apr 4;22(1):364. doi: 10.1186/s12885-022-09354-1.
7
Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.调强放疗在颅底侵犯鼻咽癌中的优势。
J Cancer Res Clin Oncol. 2020 Feb;146(2):429-439. doi: 10.1007/s00432-019-03067-y. Epub 2019 Nov 1.
8
Intensity-modulated proton and carbon-ion radiation therapy in the management of major salivary gland carcinomas.调强质子和碳离子放射治疗在大唾液腺癌管理中的应用
Ann Transl Med. 2022 Nov;10(22):1195. doi: 10.21037/atm-20-7988.
9
Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study.探讨同步化疗在II期鼻咽癌中的应用价值:一项回顾性研究。
Front Pharmacol. 2021 Sep 21;12:688528. doi: 10.3389/fphar.2021.688528. eCollection 2021.
10
Outcome of Adenoid Cystic Carcinoma of Head and Neck After Postoperative Intensity Modulation Radiotherapy: A Single Institution Study.头颈部腺样囊性癌术后调强放疗的疗效:一项单机构研究
Cancer Manag Res. 2021 Mar 15;13:2411-2417. doi: 10.2147/CMAR.S283494. eCollection 2021.

引用本文的文献

1
The Current Position of Postoperative Radiotherapy for Salivary Gland Cancer: A Systematic Review and Meta-Analysis.唾液腺癌术后放疗的现状:系统评价与Meta分析
Cancers (Basel). 2024 Jun 28;16(13):2375. doi: 10.3390/cancers16132375.
2
Systemic therapies for salivary gland carcinomas: an overview of published clinical trials.涎腺癌的系统治疗:已发表临床试验概述。
Med Oral Patol Oral Cir Bucal. 2024 Mar 1;29(2):e280-e287. doi: 10.4317/medoral.26264.
3
Radiotherapy for primary thyroid adenoid cystic carcinoma.原发性甲状腺腺样囊性癌的放射治疗
Open Life Sci. 2023 Mar 7;18(1):20220547. doi: 10.1515/biol-2022-0547. eCollection 2023.
4
Nomogram-Based Prediction of Overall and Disease-Specific Survival in Patients With Postoperative Major Salivary Gland Squamous Cell Carcinoma.基于列线图的术后大涎腺鳞状细胞癌患者总生存和疾病特异性生存预测。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221117405. doi: 10.1177/15330338221117405.

本文引用的文献

1
Apparent diffusion coefficient measurement of the parotid gland parenchyma.腮腺实质的表观扩散系数测量
Quant Imaging Med Surg. 2021 Aug;11(8):3812-3829. doi: 10.21037/qims-20-1178.
2
Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome.丹麦唾液腺癌:发病率、组织学和预后的国家更新和随访。
Eur Arch Otorhinolaryngol. 2021 Apr;278(4):1179-1188. doi: 10.1007/s00405-020-06205-2. Epub 2020 Jul 20.
3
Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.罕见高级别“涎腺”腺癌的结局和处理:辅助(放)化疗的重要作用。
Strahlenther Onkol. 2019 Dec;195(12):1050-1059. doi: 10.1007/s00066-019-01499-6. Epub 2019 Jul 26.
4
Survival and characteristics of pediatric salivary gland cancer: A systematic review and meta-analysis.儿童唾液腺癌的生存和特征:系统评价和荟萃分析。
Pediatr Blood Cancer. 2019 Mar;66(3):e27543. doi: 10.1002/pbc.27543. Epub 2018 Oct 30.
5
Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2 N0 high-grade salivary gland cancer.转移性和局限性高级别唾液腺癌的治疗结果:T1-2N0 高级别唾液腺癌患者,手术和术后放疗有很大治愈机会。
BMC Cancer. 2018 Jun 20;18(1):672. doi: 10.1186/s12885-018-4578-0.
6
Cervical Lymph Node Metastatic Status and Adjuvant Therapy Predict the Prognosis of Salivary Duct Carcinoma.颈部淋巴结转移状态及辅助治疗可预测涎腺导管癌的预后。
J Oral Maxillofac Surg. 2018 Jul;76(7):1578-1586. doi: 10.1016/j.joms.2018.01.033. Epub 2018 Feb 19.
7
Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?调强放射治疗能否降低头颈部鳞状细胞癌的毒性?
Cancers (Basel). 2017 Oct 6;9(10):135. doi: 10.3390/cancers9100135.
8
Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation.接受手术及术后放疗的头颈部腺样囊性癌患者的长期局部控制率。
Laryngoscope. 2017 Oct;127(10):2265-2269. doi: 10.1002/lary.26565. Epub 2017 Mar 21.
9
Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma.对于T4期鼻咽癌,与三维适形放射治疗相比,调强放射治疗能实现更好的局部控制。
Oncotarget. 2017 Feb 21;8(8):14068-14077. doi: 10.18632/oncotarget.12736.
10
Incidence and survival rates for malignant salivary gland tumors.恶性涎腺肿瘤的发病率和生存率。
J Oral Sci. 2016;58(1):67-73. doi: 10.2334/josnusd.58.67.